Compassionate drug (mis)use during pandemics: lessons for COVID-19 from 2009.
Amanda M RojekGenevieve E MartinPeter W HorbyPublished in: BMC medicine (2020)
Patients were frequently treated for pandemic influenza with drugs not registered for this indication, but rarely under circumstances of high-quality data capture. The result was a reliance on use under compassionate circumstances, resulting in continued uncertainty regarding the potential benefits and harms of anti-viral treatment. Rapid scaling of clinical trials is critical for generating a quality evidence base during pandemics.
Keyphrases
- sars cov
- coronavirus disease
- clinical trial
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- electronic health record
- machine learning
- patient reported outcomes
- risk assessment
- big data
- deep learning
- data analysis
- phase ii
- artificial intelligence
- study protocol
- double blind
- placebo controlled
- sensitive detection